Literature DB >> 2421869

Establishment of a high production system for AIDS retroviruses with a human T-leukemic cell line Molt-4.

Y Koyanagi, S Harada, N Yamamoto.   

Abstract

A cell culture system was developed for the continuous and efficient production of acquired immune deficiency syndrome (AIDS) retrovirus. After infection of a human T-cell line Molt-4 with HTLV-III and LAV the cells grow permanently and produce large amounts of virus continuously. The yields of production of virus were assessed either with reverse transcriptase activity or a newly established biological quantitation assay of active virus. The amounts of virus with this cell system were much higher than those of the H9 cell system. This procedure enabled us first to compare the two viral isolates HTLV-III and LAV directly in the same cell line. Establishment of the culture system, allowing efficient production of AIDS retroviruses, provides a useful tool for the isolation of the virus from patients with AIDS and for more basic research, such as the mechanisms of immune destruction caused by the virus leading to the occurrence of various malignancies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421869     DOI: 10.1016/0304-3835(86)90054-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  Characterization of human T-cell lines harboring defective human immunodeficiency virus type 1.

Authors:  Y Hamamoto; K Takamatsu; S Kobayashi; K Yamaguchi; N Yamamoto; N Kobayashi
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

2.  Effect of retinoic acid on the replication of human immunodeficiency virus in HTLV-I-positive MT-4 cells.

Authors:  H Nakashima; S Harada; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

3.  Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae.

Authors:  H Nakashima; Y Kido; N Kobayashi; Y Motoki; M Neushul; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  Replication of human immunodeficiency virus: yield of infectious virus under single growth cycle conditions.

Authors:  F Dianzani; G Antonelli; M R Capobianchi; F De Marco
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

5.  Evaluation of passive particle agglutination test for antibody to human immunodeficiency virus.

Authors:  T Yoshida; T Matsui; S Kobayashi; N Yamamoto
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

6.  Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives.

Authors:  S Shibahara; S Mukai; H Morisawa; H Nakashima; S Kobayashi; N Yamamoto
Journal:  Nucleic Acids Res       Date:  1989-01-11       Impact factor: 16.971

7.  Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins.

Authors:  Kei Sato; Jun Aoki; Naoko Misawa; Eriko Daikoku; Kouichi Sano; Yuetsu Tanaka; Yoshio Koyanagi
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

8.  Evaluation of anti-human immunodeficiency virus effect of recombinant CD4-immunoglobulin in vitro: a good candidate for AIDS treatment.

Authors:  I H Chowdhury; Y Koyanagi; K Takamatsu; O Yoshida; S Kobayashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

9.  Inhibition (in vitro) of replication and of the cytopathic effect of human immunodeficiency virus by an extract of the culture medium of Lentinus edodes mycelia.

Authors:  T S Tochikura; H Nakashima; Y Ohashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

10.  Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.

Authors:  M A el-Farrash; M J Kuroda; T Kitazaki; T Masuda; K Kato; M Hatanaka; S Harada
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.